How big is Editas Medicine, Inc.?

As of Jun 18, Editas Medicine, Inc. has a market capitalization of 179.15 million and reported net sales of 35.83 million, with a net profit loss of 251.24 million. Shareholder's funds are 134.27 million, and total assets amount to 341.59 million.

As of Jun 18, Editas Medicine, Inc. has a market capitalization of 179.15 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 35.83 million for the latest four quarters. However, it also experienced a net profit loss of 251.24 million during the same period.<BR><BR>As of Dec 24, the reporting period shows that Editas Medicine, Inc. has shareholder's funds amounting to 134.27 million and total assets of 341.59 million.

What does Editas Medicine, Inc. do?

Editas Medicine, Inc. is a genome editing company focused on treating genetically defined diseases, with a market cap of $179.15 million and recent quarterly net sales of $5 million, but a net loss of $76 million. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap firm.

Overview:<BR>Editas Medicine, Inc. is a genome editing company engaged in treating patients with genetically defined diseases and operates within the Pharmaceuticals & Biotechnology industry, classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 5 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -76 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 179.15 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -3.33 <BR>Return on Equity: -317.44% <BR>Price to Book: 2.87<BR><BR>Contact Details:<BR>Address: 11 Hurley St, CAMBRIDGE MA: 02141-2110 <BR>Tel: 1 617 4019000, 1 617 4019083 <BR>Fax: 1 302 6555049 <BR>Website: http://www.editasmedicine.com/

Should I buy, sell or hold Editas Medicine, Inc.?

Who are in the management team of Editas Medicine, Inc.?

As of March 2022, the management team of Editas Medicine, Inc. includes Independent Chairman Mr. James Mullen, President and CEO Ms. Cynthia Collins, and several independent directors: Dr. Meeta Chatterjee, Mr. Andrew Hirsch, Dr. Jessica Hopfield, Dr. David Scadden, and Dr. Akshay Vaishnaw. This team provides governance and strategic direction for the company.

As of March 2022, the management team of Editas Medicine, Inc. includes the following individuals:<BR><BR>- Mr. James Mullen, who serves as the Independent Chairman of the Board.<BR>- Ms. Cynthia Collins, who is the President, Chief Executive Officer, and a Director.<BR>- Dr. Meeta Chatterjee, who is a Director.<BR>- Mr. Andrew Hirsch, who is an Independent Director.<BR>- Dr. Jessica Hopfield, who is an Independent Director.<BR>- Dr. David Scadden, who is an Independent Director.<BR>- Dr. Akshay Vaishnaw, who is an Independent Director. <BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Is Editas Medicine, Inc. overvalued or undervalued?

As of March 30, 2016, Editas Medicine, Inc. is considered overvalued and risky due to its high Price to Book Value of 2.56 and low EV to EBITDA of 0.24, despite a strong ROCE of 142.55% and poor ROE of -317.44%, while its recent stock performance shows a significant year-to-date return of 136.22% but a 1-year decline of -22.68%, contrasting with the S&P 500's gains.

As of 30 March 2016, the valuation grade for Editas Medicine, Inc. moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 2.56 and an EV to EBITDA of 0.24, which suggest that the market is pricing the company at a premium despite its losses. Additionally, the ROCE stands at an impressive 142.55%, but this is overshadowed by a concerning ROE of -317.44%, reflecting significant financial distress.<BR><BR>In comparison to its peers, Kura Oncology, Inc. has a more pronounced EV to EBITDA ratio of -0.3981, while Curis, Inc. stands at -1.1288, both indicating a more favorable valuation relative to Editas. The recent stock performance shows that while Editas has outperformed the S&P 500 on a year-to-date basis with a return of 136.22% compared to 12.22%, it has significantly underperformed over the longer term, with a 1-year return of -22.68% versus 17.14% for the index. This discrepancy reinforces the notion that Editas may be overvalued in the current market environment.

Is Editas Medicine, Inc. technically bullish or bearish?

As of September 10, 2025, Editas Medicine, Inc. shows a mildly bullish technical trend with mixed signals from key indicators, having outperformed the S&P 500 in the short term but significantly underperformed over the past year.

As of 10 September 2025, the technical trend for Editas Medicine, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The weekly RSI shows no signal, but the monthly RSI is bullish. Daily moving averages are bullish, indicating positive short-term momentum. However, the weekly KST is mildly bearish, and the monthly KST is mildly bullish, suggesting mixed signals. The Dow Theory indicates a mildly bullish stance on a weekly basis, but no trend on a monthly basis. The OBV is mildly bullish weekly but mildly bearish monthly, adding to the mixed outlook.<BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 10.70% and 9.89% respectively, compared to 1.05% and 2.33% for the index. However, over longer periods, such as the past year and beyond, the stock has underperformed significantly, with a 1Y return of -22.68% versus the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, with key indicators showing a mix of strength and weakness.